Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical overview on moclobemide

J W Tiller1

  • 1Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The identification and treatment of depression by general practitioners.

The Australian and New Zealand journal of psychiatry·2002
Same author

Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2000
Same author

Cade's observation of the antimanic effect of lithium and early Australian research.

The Australian and New Zealand journal of psychiatry·2000
Same author

An open study of sertraline in patients with major depression who failed to respond to moclobemide.

The Australian and New Zealand journal of psychiatry·2000
Same author

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

European archives of psychiatry and clinical neuroscience·1999
Same author

Liability in prescribing choice: the example of the antidepressants.

The Australian and New Zealand journal of psychiatry·1998

Moclobemide, a reversible inhibitor of monoamine oxidase A, demonstrates efficacy across various depression types in adults and the elderly. It offers better tolerability and safety than older antidepressants, with fewer dietary restrictions and drug interactions.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Depressive disorders represent a significant global health burden.
  • Existing antidepressant therapies have limitations regarding efficacy, side effect profiles, and safety in overdose.
  • Novel therapeutic agents with improved safety and tolerability are needed.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of moclobemide, a reversible inhibitor of monoamine oxidase A (RIMA).
  • To compare moclobemide's profile with established antidepressant classes.
  • To assess the practical aspects of moclobemide use, including dietary interactions and contraindications.

Main Methods:

  • Clinical trials assessing moclobemide in patients with endogenous and non-endogenous depression.

Related Experiment Videos

  • Comparative studies evaluating efficacy against tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).
  • Safety assessments including tolerability, overdose effects, and drug-drug interactions.

    • Main Results:

    • Moclobemide shows significant clinical efficacy in a broad spectrum of depressive illnesses in both younger adults and the elderly.
    • It exhibits comparable efficacy to main antidepressant classes but with superior tolerability and safety, especially in overdose compared to TCAs.
    • Moclobemide is neither sedative nor alerting, requires no dietary restrictions on a normal diet, and has few, generally mild, drug interactions.

    Conclusions:

    • Moclobemide is a valuable and effective antidepressant option for diverse patient populations.
    • Its favorable safety and tolerability profile, coupled with comparable efficacy, make it a significant advancement in depression treatment.
    • Moclobemide represents a useful addition to the clinical armamentarium for managing depressive disorders.